Anthropic tests Claude on de novo protein binder design
With an expert-written prompt, Claude autonomously designed binders against 14 out of 15 targets; between 22% and 35% bound successfully.
- Adaptyv Bio and Twist Bioscience independently built and tested the proteins Claude designed.
- The typical success rate in the field is between 10% and 15%.
- Some designs bound several times more tightly than the best published de novo binder.
- Protein binders are not drugs; high-affinity binding is only an initial step toward developing a safe and effective treatment.
- Anthropic published a technical report and open-sourced the experiment’s prompts and data on Hugging Face.
Protein researchers now have evidence and open resources showing Claude can produce novel, experimentally validated binders, although these remain far from finished drugs.
Sources
Read this as text
Back to the AI news